Received Mar 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (QUADRACEL) | SANOFI PASTEUR | 4 | U7838AA | IM |
| FLU3 | INFLUENZA (SEASONAL) (FLUCELVAX) | SEQIRUS, INC. | 1 | 946602 | IM |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 2 | Y006767 | SC |
Pt. received Sanofi Pasteur Quadracel, Merck ProQuad and Sequirus Flucelvax at his routine 4 year well. Within minutes of receiving the vaccine, he described throat itching. His skin became itchy but he did not develop hives. The physician was immediately notified and assessed the patient. He did not develop any respiratory distress. He was given oral Diphenhydramine and oral Dexamethasone and observed in the office until all his symptoms had resolved. Physician followed up by phone later in the day and the patient had no further symptoms.
none
none
none
none